Adalimumab for Children with Severe Plaque Psoriasis
Treatments studied
Part of Skin clinical trials.
This study tests whether adalimumab, a biologic medication given by injection, can safely and effectively treat severe plaque psoriasis in children. It may help children whose current treatments haven't worked or aren't suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 4 and 17 years old, and weigh at least 33 pounds (15 kg).
- Child must have been diagnosed with severe plaque psoriasis that topical treatments (like creams) or light therapy haven't helped, or that those treatments aren't right for.
- Child must not have had certain psoriasis treatments like psoralen plus UVA within 14 days, UVB therapy within 7 days, or non-biologic systemic medicines within 14 days before the study starts.
- Child must not have used biologic drugs (like certain injectable medications) within the last 12 weeks.
- Child's psoriasis must be stable enough (not severely flaring up) in the 12 weeks before they start the study.
- Child must not have had a live vaccine in the past 3 months, and must not plan to get one during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well and how safely a medicine called adalimumab works in children ages 6–17 with moderate-to-severe Crohn's disease (a condition causing inflammation in the digestive tract). Your child's doctor has already decided adalimumab is appropriate for them, and this study simply collects information about how they respond to it.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study tests a new medication called SHR-1314 for teenagers aged 6 to under 18 with moderate to severe plaque psoriasis. It aims to see if the treatment is safe and effective in reducing psoriasis symptoms.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
Hear when a new Severe Plaque Psoriasis in Chinese Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.